In patients with diabetes, intraday glucose variability might predict health outcomes independently from glycosylated hemoglobin (HbA 1c ).
M
aintaining glycosylated hemoglobin (HbA 1c ) less than 7.0% in persons with either type 1 or type 2 diabetes has been shown to reduce microvascular and some macrovascular complications (1, 2). Current treatment guidelines recommend maintaining HbA 1c below 7.0% (3) or no more than 6.5% (4) for most patients with diabetes. If target levels are not met, diet, exercise, and diabetes medications are adjusted accordingly.
HbA 1c represents average glucose for the previous 2-3 months, but similar HbA 1c levels can be achieved with a wide range of fasting, preprandial, and postprandial glucose levels. For type 1 and insulin-treated type 2 diabetes patients failing to achieve target goals, insulin can be increased and the number of injections and types of insulin varied. Insulin titration algorithms based upon self-monitored fasting, preprandial and/or postprandial glucose levels, and the occurrence of hypoglycemia are tools for adjusting insulin. However, dose escalation is often hampered by fluctuating glucose excursions, fear of hypoglycemia, and the associated symptoms of hypoandhyperglycemia.Suchexcursionsarenotfullyreflectedinthe typical daily measures of self-monitored blood glucose, mean daily glucose, or HbA 1c , making clinical management even more difficult. However, such excursions can be detected using continuous glucose monitoring (CGM) and summarized using glycemic variability indices (5-7). One study concluded that glycemic variability is one of the components of glycemic disorders in patients with diabetes and that the use of CGM will need to be increased to promote better assessment and management of glycemic variability in both type 1 and type 2 diabetes (8) . Another study found that a CGM system had a positive effect on the self-management of diabetes by lowering glycemic variability (9) .
A recent review concluded that ambulatory 24-h glucose should be considered in addition to HbA 1c and fasting glucose when evaluating the comparative effectiveness of therapeutic regimens (10) . In addition, there is evidence that glycemic variability might be an independent risk factor for longer-term vascular complications (11) (12) (13) . However, other studies have found that HbA 1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycemia or glucose variability in persons with diabetes (14) . Although results demonstrating that glycemic variability as a cause of longer-term diabetes complications are inconclusive, it has been shown to be related to shorter-term outcomes such as behavioral changes in children (15) and hypoglycemia (16) . One small sample of 36 patients studied at one point in time found that although levels of high glucose were associated with poorer mood ratings, glycemic variability was not found to be an independent predictor (17) .
Patient-centered outcomes such as regimen burden, convenience, and adverse side effects also impact therapeutic effectiveness in achieving target HbA 1c by limiting the ability to intensify therapy. We demonstrated previously that reduced HbA 1c is associated with quality-of-life (QoL) and health economic benefits (18) ; however, evidence as to whether glycemic variability is associated with QoL and patient satisfaction, both of which might impact insulin intensification, is lacking. To draw a valid causal inference between the effects of glycemic variability and patient-centered outcomes such as satisfaction and QoL, which might impact the ability to intensify therapy, requires a longitudinal, crossover clinical trial design randomizing patients to regimens that produce systematic differences in glycemic variability. In this way, variables that might confound the effects of the hypothesized association are minimized.Becausebasal-bolusinsulinregimensmorecloselymimic the physiological requirements for insulin, such regimens could potentially result in a smoother, less variable 24-h glucose profile at the same level of HbA 1c compared with conventional insulin regimens.
The primary objective of this study was to determine whether less variable glucose profiles might positively impact patient acceptance and QoL, thus offsetting the burden of additional injections, reducing hypoglycemia with increasing doses, and increasing the probability of reaching target HbA 1c . To investigate this hypothesis, we evaluated patient satisfaction, QoL, HbA 1c , and glycemic variability in type 1 and insulin-treated type 2 diabetes patients randomized to either a basal-bolus regimen of insulin glargine plus premeal insulin glulisine or to premix analog insulin during a 6-month, multicenter, randomized, crossover clinical trial.
Materials and Methods

Design overview
This comparative effectiveness trial included a screening visit, 3-wk lead-in period, and two 12-wk treatment (crossover) phases. During lead-in, patients remained on their preexisting insulin regimen and, if applicable, oral antihyperglycemic agents. Subjects received training on the Medtronic CGMS System Gold (blinded CGM), electronic hand-held personal digital assistant (e-diary), and self-monitoring of blood glucose (SMBG), including recording glucose, insulin doses, and symptoms of hypo-or hyperglycemia. They transmitted e-diary data daily to the central server (Phase V Technologies, Wellesley Hills, MA) using the personal digital assistant's wireless acoustic modem and a land-line telephone handset.
Setting and participants
Six hundred eighty individuals with either type 1 or insulintreated type 2 diabetes for at least 6 months were screened at 58 centers in the United States. Inclusion criteria were age 21-70 yr; stable on premix 75/25 or 70/30 insulin, neutral protamine Hagedorn, or insulin glargine with short-acting insulin, consisting of two injections daily, with or without concomitant oral medications (metformin, thiazolidinedione, and/or ␣-glucosidase inhibitor) for 3 months before screening; baseline HbA 1c 7.0% or higher and no higher than 9.0%; employed, unpaid work, or active lifestyle; and able to read English at the sixthgrade level. Exclusion criteria included significant cardiac disease, cancer, or laboratory abnormalities; insulin pump or concomitant oral diabetes medications not listed above; and inability to complete a 72-h CGM session after three attempts during the lead-in period before randomization. The protocol was approved by the institutional review board at each center, and informed consent was obtained from all subjects.
Randomization and interventions
As outlined in Fig. 1 
Outcomes and follow-up
HbA 1c was measured at wk 0 (baseline), 4, 8, 12, 16, 20 , and 24. Fasting plasma glucose was measured at wk 0, 4, 12, 16, and 24 and lipids at wk 0, 12, and 24. Hypoglycemic events, adverse events, standard clinical chemistry and hematology, physical examinations, vital signs, and weight were measured at baseline and follow-up clinic visits. At wk Ϫ3, 0, 8, 12, 20, and 24, and at early withdrawal, patient-reported outcomes questionnaires were completed at the clinic and sent to the survey center (Phase V Technologies). Questionnaires consisted of validated generic and diabetes-specific modules of treatment satisfaction, QoL, and barriers to insulin adherence (19, 20) (see Supplemental Appendix 2 for listing of scales and subscales). These measures have been used by the authors previously and found to be responsive to the effects of therapeutic interventions (21) (22) (23) and the impact of side effects of medication (24) , symptoms of diabetes (25) (26) (27) , changes in HbA 1c (18, 28 -30) , diabetes-related treatment satisfaction, and diabetes-related weight changes (31) . All scales were coded such that higher scores reflected more favorable responses.
Blinded CGM for 72 consecutive hours was conducted before baseline (wk Ϫ2 to Ϫ1), the end of period 1 (wk 10 -12), and the end of period 2 (wk [22] [23] [24] . If the initial CGM session was not adequate, it was repeated a second or third time as required. CGM measures included mean daily sensor glucose (average of 288 values across days within a session), glycemic variability as measured by the intra-day glucose SD (sensor glucose SD within a calendar day averaged across days within a session), and percent time sensor glucose was below 70 mg/dl (3.9 mmol/liter) or above 140 mg/dl (7.8 mmol/liter). For the e-diary blood glucose data, the glucose value from the meter was considered the gold standard.
Statistical analysis
The net benefit patient satisfaction scale and the QoL factor score were the prespecified co-primary endpoints sharing ␣ of 0.05 and each required to achieve statistical significance at ␣ ϭ 0.031 using a modified Bonferroni adjustment for correlated endpoints. Treatment effects were analyzed for each QoL and treatment satisfaction scale using a linear mixed model. Weeks 8, 12, 20 , and 24 were the repeated-measures dependent variables; wk 0 and 12 (baseline for periods 1 and 2, respectively) were used as covariates. Period and sequence were fixed effects. Other effects and covariates (age, gender, center, type of diabetes, and race) were evaluated. Laboratory and CGM data were analyzed using similar models. Rates of hypoglycemia were analyzed using negative binomial models. All other variables were secondary endpoints for which P values report nominal significance. Linear mixed models and logistic regression were used to examine relationships between treatment, HbA 1c , CGM glycemic control and variability, satisfaction, and QoL. Data are given as means Ϯ SE unless specified otherwise.
Results
Study accrual, withdrawals, and baseline characteristics
Study accrual (82 type 1 and 306 type 2 diabetes patients), allocation, and reasons for withdrawal are detailed in Fig. 1 . Withdrawal was similar between groups for period 1; however, during period 2, four times as many patients in the premix arm withdrew compared with the glargine-glulisine arm (P Ͻ 0.001). Baseline demographics and clinical characteristics did not differ between initial treatment allocations (Table 1) .
HbA 1c , fasting plasma glucose, target goals, weight, hypoglycemia, and adverse events
Baseline-adjusted HbA 1c and fasting plasma glucose at the ends of periods 1 and 2 and combined across both periods adjusting for covariates were significantly lower Demographic and previous medication data are presented as n (percent). Clinical data are presented as mean Ϯ SD, with ranges in parentheses. a Four subjects in glargine-glulisine and two subjects in premix did not report marital status.
for glargine-glulisine vs. premix (Table 2) . Period, type of diabetes (both P Ͻ 0.001), and race (P ϭ 0.025) effects were statistically significant covariates, whereas sequence (P ϭ 0.79), sex (P ϭ 0.41), center (P ϭ 0.12), and age (P ϭ 0.67) effects were not. The frequency and severity of hypoglycemia (Table 3) and nonhypoglycemic adverse events were comparable for the two insulin regimens.
Patient-reported outcomes
As shown in Table 4 , baseline overall satisfaction of 61.3 indicated that patients were moderately satisfied with their lead-in insulin treatment (0 for greatest dissatisfaction to 100 for highest satisfaction). The co-primary net benefit satisfaction scale improved for glargine-glulisine compared with worsening with premix. All net benefit subscales (advocacy, preference, perceived efficacy and general satisfaction) demonstrated a significantly greater improvement for glargine-glulisine compared with premix. There was a more positive treatment impact on net benefit for glargine-glulisine vs. premix in type 1 compared with type 2 diabetes (P Ͻ 0.0001). The four net benefit subscales also showed greater improvement for type 1 compared with type 2 diabetes (all P Ͻ 0.0001). The (Table 4) . QoL scales generally showed significant improvement for glargine-glulisine vs. a worsening for premix. The overall mental health composite scale trended toward improvement for glargine-glulisine vs. worsening for premix. Type of diabetes was not a significant treatment-effect modifier of the QoL factor score.
CGM, SMBG, and insulin titration
During CGM, the mean daily sensor glucose, intra-day sensor glucose SD, and percent time sensor glucose was above 140 mg/dl (7.8 mmol/liter) all decreased significantly more for glargine-glulisine compared with premix (P Ͻ 0.0001) ( Table 5 ). CGM percent time below 70 mg/dl (3.9 mmol/liter) (hypoglycemia) was not statistically significantly different between glargine-glulisine and premix. Consistent with the sensor glucose SD results, the fourpoint SMBG profiles indicated more variation before meals and bedtime for premix compared with glargineglulisine. The total daily insulin dose during months 1-3 increased by 31.3% for patients starting on glargine-glulisine and by 16.0% for those starting on premix (Table 6 ). During months 4 -6, insulin dose increased by 14.3% for those switching to glargine-glulisine and by 12.4% for those switching to premix.
Associations between HbA 1c , CGM parameters, treatment satisfaction, and QoL
Each 10-point increase in net benefit during treatment increased the likelihood of reaching target HbA1c below 7.0% by 10% [odds ratio ϭ 1.10 (95% confidence interval ϭ 1.02-1.18, P ϭ 0.014)] after adjusting for baseline HbA 1c (P Ͻ 0.0001), baseline net benefit (P ϭ 0.004), and type of diabetes (P ϭ 0.013). Age, gender, and duration of diabetes were not significant predictors. Change in HbA 1c , CGM sensor glucose, and CGM sensor glucose SD were all independent predictors of the net benefit scale. For each percent unit decrease in HbA 1c , patient satisfaction improved by (mean Ϯ SE) 4.7 Ϯ 1.2 units (P Ͻ 0.0001); for each 10 mg/dl (0.6 mmol/liter) decrease in mean sensor 
Discussion
The importance of intensive glucose control for preventing diabetes-related complications is well established (1, 2, 32). However, individuals with type 1 and type 2 diabetes frequently fail to achieve HbA 1c goals of less than 7.0% or no more than 6.5% recommended by professional organizations (3, 4) . This failure often arises from reluctance by patients or physicians to increase insulin dose due to fear of hypoglycemia. For patients with type 2 diabetes poorly controlled on diet and oral agents, insulin treatment is often delayed because of the perceived burden of injections and glucose self-monitoring, weight gain, and risk of hypoglycemia. For those patients already on insulin, similar concerns also impede insulin intensification. Target glycemia measures such as HbA 1c and fasting plasma glucose often fail to distinguish between highly fluctuating glucose profiles and those that are more stable. Although the impact of postprandial glycemic excursions has been investigated in relation to longer-term complications, oxidative stress, and microvascular pathology (11) (12) (13) , the greatest impact of reduced glycemic variability might be to facilitate patient acceptance, allowing greater insulin intensification.
When evaluating the comparative effectiveness of insulin regimens, glycemic variability, satisfaction, and QoL might provide additional evidence of therapeutic benefit. To date, there have been no quantitative studies demonstrating an association between decreased glycemic variability, improved patient satisfaction and QoL, and higher probability of reaching goal HbA 1c . In healthy adults, normal physiological insulin secretion prevents widely varying glucose fluctuations. However, for the diabetes patient, defects in insulin secretion cause both chronic sustained hyperglycemia and acute daily fluctuations in glucose levels corresponding to meals, exercise, and diabetes medications. The prevalence of high and low excursions might not be reflected in either standard four-point glucose profiles or HbA 1c but can be quantified using 24-h ambulatory glucose monitoring.
Insulin intensification algorithms facilitate achieving target HbA 1c by dose adjustments according to SMBG (33, 34) . Patient-centered outcomes such as tolerability, burden, convenience, and QoL are key factors that influence the ability to adhere to insulin adjustments. For patients injecting insulin once or twice daily, basal-bolus insulin regimens might also be postponed because of the perceived burden of additional injections and glucose selfmonitoring (35) . However, such regimens might confer benefits associated with a more physiological nondiabetic intra-day glucose profile that could potentially offset regimen burden.
By optimizing the clinician's ability to follow the algorithm, insulin dose increases could be maximized according to daily fasting and premeal glucose levels in a standardized fashion across centers. Insulin doses increased each month; however, in the glargine-glulisine arm, the increase during the first period was approximately twice as high as in the premix group, the dropout rate during the second period was four times lower, and patient satisfaction and QoL outcomes were significantly higher. Rates of hypoglycemia were comparable. The lowering of HbA 1c was significantly greater for glargine-glulisine vs. premix by 0.33%. However, this difference alone did not account for the improvement in satisfaction or QoL outcomes. Rather, both CGM sensor glucose mean and SD were independent predictors.
Our results indicate that for insulin-using patients treated with two daily injections of insulin and moderately satisfied with their current therapy, there is opportunity to improve acceptance of insulin treatment while increasing the probability of reaching HbA 1c goals using a basalbolus regimen. As expected, the impact was greater for patients with type 1 diabetes because it is much more difficult to control glycemic excursions in this population. Studies have suggested that ease of use, convenience, social comfort, and flexibility of the treatment process are important issues to both type 1 and type 2 diabetic patients for insulin administration (36, 37) . While on glargineglulisine, patients reported substantial and stable improvement in satisfaction ratings in contrast to no change or worsening for those on premix. Our findings documented that fewer patients withdrew from the glargine-glulisine regimen as insulin was intensified, and patients had a 50% higher probability of achieving target HbA 1c below 7.0%. They also had improved health perceptions, QoL, and satisfaction when on the glargine-glulisine regimen. These results are consistent with previous studies showing higher satisfaction in patients on insulin pumps, which also more closely mimic the body's insulin requirements (38, 39) .
During a period of carefully monitored insulin titration, maximum effectiveness of glycemic control, treatment satisfaction, and QoL outcomes can be achieved using a basal-bolus regimen such as insulin glargine plus glulisine compared with a simpler regimen using premix analog insulin. One of the major concerns that creates barriers to adoption of insulin and intensification is the perception that patients will fail to adhere to a more complex insulin regimen. However, we have demonstrated that overall regimen acceptance was comparable between the two treatment arms. This finding supports the general recommendation that multiple injections using a basalbolus insulin regimen can be used by patients and that improved health outcomes appear to offset the impact of increased burden associated with the insulin regimen.
Limitations of this study included the open-label design and the relatively short duration of each treatment period. Although the gold standard for clinical trials is to use a double-blind design, insulin-treated diabetes requiring daily insulin adjustments by the patient must be open label to ensure patient safety. In addition, to adequately evaluate treatment satisfaction and QoL, the number of injections must reflect the actual regimen without the bias of additional saline injections required for blinding. The 3-month duration of each period was chosen to achieve a steady-state measure of HbA 1c ; however, this limited the endpoints to shorter-term patient-centered outcomes.
The CGM measures indicated decreased intra-day mean glucose, glycemic variability, and excursions above 140 mg/dl (7.8 mmol/liter), which were associated with improvements in patient satisfaction and perceived health independent of concurrent lowering of daily glucose and HbA 1c . As such, this study provides important and significant evidence that glycemic variability mediates improvements in patient-centered outcomes and should be considered when evaluating the comparative effectiveness of insulin regimens. The barriers to diabetes management are multifactorial, but our comparative effectiveness crossover trial supports the hypothesis that glycemic variability plays an important role in patient satisfaction with insulin therapy. Increased communication between clinicians and patients concerning these patient-centered factors, especially in individuals failing to intensify or maintain their insulin regimen, might better inform the clinical decision process when weighing the risks and benefits of alternative methods of delivering intensive insulin regimens.
